Improving Global News Today

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...

Chronic kidney disease (CKD) represents a global public health crisis, but awareness by patients and providers is poor. Defined as persistent abnormalities in kidney structure or function for more than three months, manifested as either low glomerular filtration rate or presence of a marker of kidney damage such as albuminuria, CKD can be identified through readily available blood and urine tests. Early recognition of CKD is crucial for harnessing major advances in staging, prognosis, and treatm...

FIGARO-BM, an exploratory human biomarker study, provides additional insight on finerenone's mechanism of action in blocking mineralocorticoid receptor (MR) overactivation1New data presented at the American Society of Nephrology’s (ASN) Kidney Week 2023WHIPPANY, N.J.--(BUSINESS WIRE)--At the American Society of Neph...

Transylvania County’s next generation of civic leaders used the year-end Democracy Project awards gala to display their interpretations of how they can participate in a democratic society.

/PRNewswire/ -- Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor –...

/PRNewswire/ -- Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor –...

Its symptoms are elusive but there are ways to combat this silent killer. Read on for what you need to know

Kidney Disease Cohort (KidDiCo) of Southern Denmark; design, coverage, generalizability and implications for use